FLT3 is an inclusion criterion in 194 clinical trials for acute myeloid leukemia, of which 114 are open and 80 are closed. Of the trials that contain FLT3 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 46 are phase 1 (22 open), 45 are phase 1/phase 2 (32 open), 74 are phase 2 (42 open), 2 are phase 2/phase 3 (1 open), 21 are phase 3 (15 open), and 4 are no phase specified (1 open) [4].

Gilteritinib, midostaurin, and sorafenib have evidence of efficacy in patients with FLT3 mutation in acute myeloid leukemia [4].

FLT3 is an inclusion criterion in 87 clinical trials for myelodysplastic syndromes, of which 51 are open and 36 are closed. Of the trials that contain FLT3 status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 25 are phase 1 (12 open), 20 are phase 1/phase 2 (15 open), 35 are phase 2 (21 open), 1 is phase 2/phase 3 (0 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 57 clinical trials for acute lymphoblastic leukemia, of which 33 are open and 24 are closed. Of the trials that contain FLT3 status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 18 are phase 1 (9 open), 7 are phase 1/phase 2 (6 open), 25 are phase 2 (14 open), 1 is phase 2/phase 3 (1 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 36 clinical trials for chronic myeloid leukemia, of which 21 are open and 15 are closed. Of the trials that contain FLT3 status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 13 are phase 1 (7 open), 7 are phase 1/phase 2 (7 open), 14 are phase 2 (7 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 25 clinical trials for chronic myelomonocytic leukemia, of which 14 are open and 11 are closed. Of the trials that contain FLT3 status and chronic myelomonocytic leukemia as inclusion criteria, 8 are phase 1 (4 open), 8 are phase 1/phase 2 (5 open), 8 are phase 2 (5 open), and 1 is phase 3 (0 open) [4].

FLT3 is an inclusion criterion in 23 clinical trials for hodgkin lymphoma, of which 12 are open and 11 are closed. Of the trials that contain FLT3 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 10 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 9 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 22 clinical trials for multiple myeloma, of which 14 are open and 8 are closed. Of the trials that contain FLT3 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 10 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 20 clinical trials for non-hodgkin lymphoma, of which 11 are open and 9 are closed. Of the trials that contain FLT3 status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 8 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 8 are phase 2 (5 open) [4].

FLT3 is an inclusion criterion in 19 clinical trials for acute biphenotypic leukemia, of which 9 are open and 10 are closed. Of the trials that contain FLT3 status and acute biphenotypic leukemia as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (4 open), 2 are phase 3 (0 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain FLT3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (4 open) [4].

FLT3 is an inclusion criterion in 13 clinical trials for mantle cell lymphoma, of which 5 are open and 8 are closed. Of the trials that contain FLT3 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 12 clinical trials for acute leukemia, of which 5 are open and 7 are closed. Of the trials that contain FLT3 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 11 clinical trials for Burkitt lymphoma, of which 4 are open and 7 are closed. Of the trials that contain FLT3 status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 10 clinical trials for myeloproliferative neoplasm, of which 6 are open and 4 are closed. Of the trials that contain FLT3 status and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (3 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 10 clinical trials for secondary acute myeloid leukemia, of which 9 are open and 1 is closed. Of the trials that contain FLT3 status and secondary acute myeloid leukemia as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [4].

FLT3 is an inclusion criterion in 9 clinical trials for anaplastic large cell lymphoma, of which 4 are open and 5 are closed. Of the trials that contain FLT3 status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 9 clinical trials for follicular lymphoma, of which 3 are open and 6 are closed. Of the trials that contain FLT3 status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 5 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 8 clinical trials for B-cell acute lymphoblastic leukemia, of which 6 are open and 2 are closed. Of the trials that contain FLT3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 8 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 5 are closed. Of the trials that contain FLT3 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 8 clinical trials for marginal zone lymphoma, of which 3 are open and 5 are closed. Of the trials that contain FLT3 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 7 clinical trials for lymphoma, of which 3 are open and 4 are closed. Of the trials that contain FLT3 status and lymphoma as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 2 (2 open), and 2 are phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 7 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 6 are open and 1 is closed. Of the trials that contain FLT3 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [4].

FLT3 is an inclusion criterion in 7 clinical trials for myelofibrosis, of which 3 are open and 4 are closed. Of the trials that contain FLT3 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 3 are phase 2 (2 open) [4].

FLT3 is an inclusion criterion in 7 clinical trials for prolymphocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain FLT3 status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 6 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 4 are closed. Of the trials that contain FLT3 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 6 clinical trials for malignant solid tumor, of which 4 are open and 2 are closed. Of the trials that contain FLT3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [4].

FLT3 is an inclusion criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain FLT3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 6 clinical trials for refractory anemia with excess blasts, of which 2 are open and 4 are closed. Of the trials that contain FLT3 status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open) and 5 are phase 2 (2 open) [4].

FLT3 is an inclusion criterion in 6 clinical trials for small lymphocytic lymphoma, of which 2 are open and 4 are closed. Of the trials that contain FLT3 status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

FLT3 is an inclusion criterion in 6 clinical trials for therapy-related acute myeloid leukemia, of which 5 are open and 1 is closed. Of the trials that contain FLT3 status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

FLT3 is an inclusion criterion in 5 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 5 are open and 0 are closed. Of the trials that contain FLT3 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [4].

FLT3 is an inclusion criterion in 5 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 1 is closed. Of the trials that contain FLT3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 5 clinical trials for lymphoblastic lymphoma, of which 4 are open and 1 is closed. Of the trials that contain FLT3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 5 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 4 are closed. Of the trials that contain FLT3 status and lymphoplasmacytic lymphoma as inclusion criteria, 4 are phase 2 (1 open) and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 5 clinical trials for T-cell acute lymphoblastic leukemia, of which 5 are open and 0 are closed. Of the trials that contain FLT3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 4 clinical trials for acute promyelocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain FLT3 status and acute promyelocytic leukemia as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (0 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 4 clinical trials for acute undifferentiated leukemia, of which 3 are open and 1 is closed. Of the trials that contain FLT3 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

FLT3 is an inclusion criterion in 4 clinical trials for adult T-cell leukemia/lymphoma, of which 0 are open and 4 are closed. Of the trials that contain FLT3 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain FLT3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

FLT3 is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain FLT3 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [4].

FLT3 is an inclusion criterion in 4 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 4 are closed. Of the trials that contain FLT3 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

FLT3 is an inclusion criterion in 4 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 2 are closed. Of the trials that contain FLT3 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 4 are phase 2 (2 open) [4].

FLT3 is an inclusion criterion in 4 clinical trials for therapy-related myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain FLT3 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 3 clinical trials for plasma cell leukemia, of which 1 is open and 2 are closed. Of the trials that contain FLT3 status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain FLT3 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].

FLT3 is an inclusion criterion in 3 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 2 are closed. Of the trials that contain FLT3 status and T-cell prolymphocytic leukemia as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for acute erythroid leukemia, of which 2 are open and 0 are closed. Of the trials that contain FLT3 status and acute erythroid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for acute megakaryoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain FLT3 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for B-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain FLT3 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain FLT3 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for myeloid sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FLT3 status and myeloid sarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for refractory anemia, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and refractory anemia as inclusion criteria, 2 are phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 2 clinical trials for waldenstrom macroglobulinemia, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for blastic plasmacytoid dendritic cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and cancer as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for hepatosplenic T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and hepatosplenic T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for langerhans cell histiocytosis, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and mast cell leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

FLT3 is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].